Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder

被引:10
作者
Elzein, Fatehi [1 ]
Albogami, Nada [2 ,3 ]
Saad, Mustafa [1 ]
El Tayeb, Nazik [1 ]
Alghamdi, Abdullah [4 ]
Elyamany, Ghaleb [2 ,3 ]
机构
[1] Prince Sultan Mil Med City, Dept Med, Div Infect Dis, Riyadh, Saudi Arabia
[2] Prince Sultan Mil Med City, Dept Cent Mil Lab, Div Hematopathol, Riyadh, Saudi Arabia
[3] Prince Sultan Mil Med City, Blood Bank, Riyadh, Saudi Arabia
[4] Prince Sultan Mil Med City, Dept Urol, Riyadh, Saudi Arabia
关键词
intravesical BCG; bladder carcinoma; disseminated BCG disease;
D O I
10.4137/CCRep.S39904
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Intravesical instillation of Bacillus Calmette-Guerin (BCG) remains a first-line treatment for superficial transitional cell carcinoma of the bladder. Although its use is relatively safe, severe complications such as granulomatous hepatitis, osteomyelitis, pneumonitis, and sepsis occur in few patients. Complications of intravesical instillation of BCG can be local or systemic, with early or late presentation. CASE PRESENTATION: Here, we report an 88-year-old man who developed fever, rigors, and episodes of syncope following fourth intravesical BCG instillation for the treatment of superficial transitional cell carcinoma of the bladder. Pancytopenia, disseminated intravascular coagulation, ground glass appearance on computerized tomography of the chest scan in addition to multiple bone marrow granulomas, suggested the diagnosis of disseminated BCG infection. All these features recovered on antituberculosis treatment. CONCLUSION: Our case study highlights the importance of early recognition and prompt treatment of patients with disseminated BCG infection following intravesical instillation. Although isolation of mycobacterium is desirable to make the diagnosis, it is not unusual to have negative smears and cultures and this should not be used to dismiss the possibility of BCG infection.
引用
收藏
页码:71 / 73
页数:3
相关论文
共 16 条
[1]   Managing the adverse events of intravesical bacillus Calmette-Guerin therapy [J].
Decaestecker, Karel ;
Oosterlinck, Willem .
RESEARCH AND REPORTS IN UROLOGY, 2015, 7 :157-163
[2]  
Fine PEM, 1999, ISSUES RELATING USE
[3]   Spectrum of Bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy [J].
Gonzalez, OY ;
Musher, DM ;
Brar, I ;
Furgeson, S ;
Boktour, MR ;
Septimus, EJ ;
Hamill, RJ ;
Graviss, EA .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :140-148
[4]  
Grange J M, 1998, Commun Dis Public Health, V1, P84
[5]   The clinical significance of CA-125 in pulmonary tuberculosis [J].
Kim, Eun Sun ;
Park, Kyoung Un ;
Song, JungHan ;
Lim, Hyo-Jeong ;
Cho, Young-Jae ;
Yoon, Hoil ;
Lee, Jaeho ;
Lee, Choon-Taek ;
Park, Jong Sun .
TUBERCULOSIS, 2013, 93 (02) :222-226
[6]   Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer [J].
Lamm, DL .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S86-S90
[7]   INCIDENCE AND TREATMENT OF COMPLICATIONS OF BACILLUS-CALMETTE-GUERIN INTRAVESICAL THERAPY IN SUPERFICIAL BLADDER-CANCER [J].
LAMM, DL ;
VANDERMEIJDEN, APM ;
MORALES, A ;
BROSMAN, SA ;
CATALONA, WJ ;
HERR, HW ;
SOLOWAY, MS ;
STEG, A ;
DEBRUYNE, FMJ .
JOURNAL OF UROLOGY, 1992, 147 (03) :596-600
[8]  
LAMM DL, 1992, UROL CLIN N AM, V19, P565
[9]   Intravesical therapies for bladder cancer - indications and limitations [J].
Logan, Callum ;
Brown, Matthew ;
Hayne, Dickon .
BJU INTERNATIONAL, 2012, 110 :12-21
[10]  
Lowther C, 2013, CUTIS, V91, P145